| Autor: |
Buburuzan L; Department of Molecular Biology, Onco Team Diagnostic S.A., 012244 Bucharest, Romania., Zamfir Irofei MA; Department of Molecular Biology, Onco Team Diagnostic S.A., 012244 Bucharest, Romania.; Department of Biochemistry and Molecular Biology, University of Bucharest, 050095 Bucharest, Romania., Ardeleanu CM; Department of Molecular Biology, Onco Team Diagnostic S.A., 012244 Bucharest, Romania., Muresan AH; Department of Molecular Biology, Onco Team Diagnostic S.A., 012244 Bucharest, Romania., Vasilescu F; Department of Molecular Biology, Onco Team Diagnostic S.A., 012244 Bucharest, Romania., Hudita A; Department of Biochemistry and Molecular Biology, University of Bucharest, 050095 Bucharest, Romania., Costache M; Department of Biochemistry and Molecular Biology, University of Bucharest, 050095 Bucharest, Romania., Galateanu B; Department of Biochemistry and Molecular Biology, University of Bucharest, 050095 Bucharest, Romania., Puscasu A; Department of Medical Oncology, Fundeni Clinical Institute, 72437 Bucharest, Romania., Filippi A; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila Bucharest, 050474 Bucharest, Romania., Motas N; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila Bucharest, 050474 Bucharest, Romania.; Clinic of Thoracic Surgery, Institute of Oncology Prof. Dr. A. Trestioreanu Bucharest, 022328 București, Romania. |
| Abstrakt: |
Lung cancer ranks second worldwide after breast cancer and third in Europe after breast and colorectal cancers when both sexes and all ages are considered. In this context, the aim of this study was to emphasize the power of dual analysis of the molecular profile both in tumor tissue and plasma by NGS assay as a liquid biopsy approach with impact on prognosis and therapy modulation in NSCLC patients. NGS analysis was performed both from tissue biopsies and from cfNAs isolated from peripheral blood samples. Out of all 29 different mutations detectable by both NGS panels (plasma and tumor tissue), seven different variants (24.13%; EGFR L858R in two patients, KRAS G13D and Q61H and TP53 G244D, V197M, R213P, and R273H) were detected only in plasma and not in the tumor itself. These mutations were detected in seven different patients, two of them having known distant organ metastasis. Our data show that NGS analysis of cfDNA could identify actionable mutations in advanced NSCLC and, therefore, this analysis could be used to monitor the disease progression and the treatment response and even to modulate the therapy in real time. |
